EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Clinical and Economic Burden Associated With Anti-Cytomegalovirus (CMV) Prophylaxis Therapies in Adult Kidney Transplant Recipients (LECOCYT): An Observational Study

Nassim Kamar, Hannah Kaminski, Christophe Masset, Claire Castagné, Guilhem Tournaire, Xavier Bourge, Lionel Bensimon, Moustafa Naja, Stéphanie Degroote, Isabelle Durand-Zaleski, Christophe Legendre

Transplant International · 2025

DOI: 10.3389/ti.2025.14342 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Transplant International, 2025. Verfasst von Nassim Kamar und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Organ Transplantation, Toulouse Rangueil University Hospital, Institut national de la santé et de la recherche médicale …. Hauptthemen laut MEDLINE: Antiviral Agents, Cytomegalovirus Infections, Kidney Transplantation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp and Dohme France.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The incidence of leukopenia and neutropenia associated with cytomegalovirus (CMV) prophylaxis in kidney transplant (KT) recipients is not well established. LECOCYT, a prospective observational multicenter study, aimed to investigate the clinical and economic burdens of CMV prophylaxis during the first 6 months post-transplantation. Grade 3 or 4 leukopenia or neutropenia was assessed in CMV-seropositive donors/CMV-seronegative recipients (D+/R-) who received current anti-CMV prophylaxis, and in CMV-seronegative donors/CMV-seronegative recipients (D-/R-) who did not. The economic burden in D+/R- was also evaluated. The adjusted odds ratio for grade 3 or 4 leukopenia or neutropenia was 5.16 [95% confidence interval: 1.97–13.53] for D+/R- group. The median costs, excluding the KT procedure, for D+/R- subgroup patients who experienced at least one episode of severe leukopenia or neutropenia were approximately €4,500 (Q1 = €561; Q3 = €10,000). D+/R- patients with no episode incurred significantly lower costs, with a median of nearly €2,100 (Q1 = €182; Q3 = €6,500) (p = 0.02). D+/R- patients with severe leukopenia or neutropenia had a higher rate of outpatient consultations than those without episode (73.9% vs. 57.6%, p = 0.002), and a higher average number of consultations per patient (5.5 ± 4.1 vs. 4.5 ± 3.3, p = 0.042) than D+/R- patients without. Anti-CMV prophylaxis in D+/R- transplant recipients was significantly associated with a higher rate of severe leukopenia or neutropenia compared to no prophylaxis in D-/R- recipients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCytomegalovirus InfectionsKidney TransplantationAdultAgedFemaleHumansMaleMiddle AgedCost of IllnessLeukopeniaNeutropeniaProspective StudiesTransplant Recipients

Stichwörter der Autor:innen

cytomegalovirus prophylaxiseconomicsganciclovirkidney transplantvalganciclovir

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Nephrology and Organ Transplantation, Toulouse Rangueil University Hospital, Institut national de la santé et de la recherche médicale - Unité Mixte de Recherche 1291 (INSERM UMR 1291), Toulouse Institute…
  • Department of Nephrology-Transplantation-Dialysis-Apheresis, University Hospital of Bordeaux, Bordeaux, France.
  • Department of Nephrology, Institut de Transplantation Urologie-Nephrologie (ITUN), Nantes University Hospital, Nantes, France.
  • MSD France, Puteaux, France.
  • ClinSearch, Malakoff, France.
  • Unité de Recherche Clinique en Économie de la Santé d'Ile de France (URC-Eco), Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Est Créteil, Créteil, France.

Förderung

  • Merck Sharp and Dohme France

Zitieren

APA

Kamar, N., Kaminski, H., Masset, C., Castagné, C., Tournaire, G., Bourge, X., Bensimon, L., Naja, M., Degroote, S., Durand-Zaleski, I., & Legendre, C. (2025). Clinical and Economic Burden Associated With Anti-Cytomegalovirus (CMV) Prophylaxis Therapies in Adult Kidney Transplant Recipients (LECOCYT): An Observational Study. Transplant International. https://doi.org/10.3389/ti.2025.14342

Vancouver

Kamar N, Kaminski H, Masset C, Castagné C, Tournaire G, Bourge X, et al. Clinical and Economic Burden Associated With Anti-Cytomegalovirus (CMV) Prophylaxis Therapies in Adult Kidney Transplant Recipients (LECOCYT): An Observational Study. Transplant International. 2025. doi:10.3389/ti.2025.14342

BibTeX
@article{Kamar2025,
  author = {Kamar, Nassim and Kaminski, Hannah and Masset, Christophe and Castagné, Claire and Tournaire, Guilhem and Bourge, Xavier and Bensimon, Lionel and Naja, Moustafa and Degroote, Stéphanie and Durand-Zaleski, Isabelle and Legendre, Christophe},
  title = {Clinical and Economic Burden Associated With Anti-Cytomegalovirus (CMV) Prophylaxis Therapies in Adult Kidney Transplant Recipients (LECOCYT): An Observational Study},
  journal = {Transplant International},
  year = {2025},
  doi = {10.3389/ti.2025.14342}
}
Kostenlos starten →